RA
ORIC icon

Royce & Associates’s Oric Pharmaceuticals ORIC Stock Holding History

Royce & Associates’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
979,664
-227,559
-19% -$2.06M 0.09% 369
2026
Q1 		$15.3M Sell
1,207,223
-300,078
-20% -$3.41M 0.15% 213
2025
Q4 		$12.3M Buy
1,507,301
+48,818
+3% +$562K 0.13% 245
2025
Q3 		$17.5M Buy
1,458,483
+1,223,709
+521% +$12.9M 0.17% 183
2025
Q2 		$2.38M Buy
+234,774
New +$1.58M 0.02% 575

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royce & Associates's ORIC Position: Q2 2026 in Review

Royce & Associates reduced its Oric Pharmaceuticals (ORIC) stake by 19% in Q2 2026, selling an estimated $2.06M and leaving 979,664 shares worth $10.6M. The position accounts for 0.09% of the portfolio, ranked #369.

Royce & Associates first reported a position in ORIC in Q2 2025 and has held it in 5 quarters since. The position peaked at $17.5M in Q3 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Royce & Associates held 979,664 shares of Oric Pharmaceuticals worth $10.6M as of Q2 2026.
  • Royce & Associates sold 227,559 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.06M.
  • Oric Pharmaceuticals made up 0.09% of Royce & Associates's portfolio in Q2 2026, its #369 holding.
  • Royce & Associates first reported a position in Oric Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Royce & Associates's Oric Pharmaceuticals position peaked at $17.5M in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.